Skip to content

Study · Non-randomized trial · n = 9 · 1995

5 results

Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue.

Kolterman OG, Gottlieb A, Moyses C, Colburn W

Diabetes care1 Aug 1995Cited by 48 (Europe PMC)

PMID7587855 (opens in a new tab)DOI10.2337/diacare.18.8.1179 (opens in a new tab)PepBankPUB-07587855
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In patients with IDDM undergoing a meal challenge, AC137 infusion yielded steady-state plasma concentrations of 225 +/- 15 pmol/l.

    In plain wordsIn patients with IDDM during a meal challenge, AC137 infusion produced steady-state blood levels of 225 +/- 15 pmol/l.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableSteady-state concentration during meal challenge
    Study

    n = 9

    Outcome group
    Pharmacokinetics · Metabolic and weight
    Studied dose
    50 micrograms/h · intravenous infusion · 5 hoursAs given in this study (human).

    Measurements

    Steady-state concentration
    225 pmol/l
    meal challenge

    Source sentences

    Summary
    Intravenous infusion of AC137 yielding steady state plasma concentrations of 225 +/- 15 pmol/l (mean +/- SE) reduced postprandial plasma glucose concentrations after the standardized Sustacal meal challenge.
    2 context sentences
    Summary · context
    Based on reasoning that an effect to modulate the appearance of orally administered glucose would have no impact on the disposition of an intravenous glucose load, nine patients were challenged with an intravenous glucose loads (300 mg/kg), while another nine patients were challenged with a standard…
    Summary · context
    On each occasion, the subjects received their usual morning doses of insulin subcutaneously.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with IDDM, AC137 reduced baseline-corrected glucose area under the curve versus placebo during the meal challenge.

    In plain wordsIn patients with IDDM, AC137 reduced the total glucose response to a meal compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseBaseline-corrected glucose area under curve
    Study

    n = 9

    Comparator
    Placebo infusion
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 micrograms/h · intravenous infusion · 5 hoursAs given in this study (human).

    Measurements

    Glucose AUC
    −1869 mg.dl-1.min
    placebo
    Glucose AUC
    −28,872 mg.dl-1.min
    AC137

    Source sentences

    Summary
    The mean area under the glucose curve, corrected for baseline, was reduced from -1,869 +/- 5,562 mg.dl-1.min during placebo infusion to -28,872 +/- 4,812 mg.dl-1.min during AC137 infusion, P = 0.0015.
    2 context sentences
    Summary · context
    Based on reasoning that an effect to modulate the appearance of orally administered glucose would have no impact on the disposition of an intravenous glucose load, nine patients were challenged with an intravenous glucose loads (300 mg/kg), while another nine patients were challenged with a standard…
    Summary · context
    On each occasion, the subjects received their usual morning doses of insulin subcutaneously.
  3. 03HumanNon-randomized trialPharmacokinetics

    In patients with IDDM undergoing intravenous glucose challenge, AC137 infusion produced steady-state concentrations of 234 +/- 16 pmol/l.

    In plain wordsIn patients with IDDM during an intravenous glucose challenge, AC137 infusion produced steady-state levels of 234 +/- 16 pmol/l.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableSteady-state concentration during intravenous glucose challenge
    Study

    n = 9

    Outcome group
    Pharmacokinetics · Metabolic and weight
    Studied dose
    50 micrograms/h · intravenous infusion · 5 hoursAs given in this study (human).

    Measurements

    Steady-state concentration
    234 pmol/l
    intravenous glucose challenge

    Source sentences

    Summary
    In contrast, an AC137 infusion producing steady-state concentrations of 234 +/- 16 pmol/l had no effect on the plasma glucose profile after administration of an intravenous glucose load.
    2 context sentences
    Summary · context
    Based on reasoning that an effect to modulate the appearance of orally administered glucose would have no impact on the disposition of an intravenous glucose load, nine patients were challenged with an intravenous glucose loads (300 mg/kg), while another nine patients were challenged with a standard…
    Summary · context
    On each occasion, the subjects received their usual morning doses of insulin subcutaneously.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with IDDM, AC137 infusion did not affect the plasma glucose profile after intravenous glucose versus placebo.

    In plain wordsIn patients with IDDM, AC137 did not change the glucose response to intravenous glucose compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changePlasma glucose after intravenous glucose load
    Study

    n = 9

    Comparator
    Placebo infusion
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    50 micrograms/h · intravenous infusion · 5 hoursAs given in this study (human).

    Source sentences

    Summary
    In contrast, an AC137 infusion producing steady-state concentrations of 234 +/- 16 pmol/l had no effect on the plasma glucose profile after administration of an intravenous glucose load.
    2 context sentences
    Summary · context
    Based on reasoning that an effect to modulate the appearance of orally administered glucose would have no impact on the disposition of an intravenous glucose load, nine patients were challenged with an intravenous glucose loads (300 mg/kg), while another nine patients were challenged with a standard…
    Summary · context
    On each occasion, the subjects received their usual morning doses of insulin subcutaneously.
  5. 05HumanNon-randomized trialEfficacy outcome

    In subjects with IDDM, AC137 infusion with usual insulin decreased postprandial hyperglycemia in the preliminary cohort.

    In plain wordsIn subjects with IDDM, AC137 infusion with usual insulin reduced high glucose after meals.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial hyperglycemia in preliminary cohort
    Study

    n = 6

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    150 micrograms/h · intravenous infusion · 2 hoursAs given in this study (human).

    Source sentences

    Summary
    After the observation that a 2-h infusion of AC137 at a rate of 150 micrograms/h, in conjunction with the subjects' usual morning insulin dose, decreased postprandial hyperglycemia in 6 subjects with IDDM,

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.